Skip to main content

Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study

Abstract

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model provides a valuable paradigm of the energy deficiency disorders found in childhood. In such disorders, anticonvulsants may provide neuroprotection by modulating cellular energy consumption and by exerting favorable pleiotropic effects on neuronal survival. To verify such hypothesis, we tested the effects of levetiracetam, vigabatrin, gabapentine, pregabaline, tiagabine, clonazepam and lamotrigine on neuroprotection in the MPTP mouse model. The membrane dopamine transporter (DAT) density, which provides a reliable index of dopaminergic neurons survival in the basal ganglia, was assessed by semi-quantitative autoradiography of the striatum. Unlike all other anticonvulsants tested, lamotrigine provided a significant and dose-dependent neuroprotection in these experimental conditions. Lamotrigine, a widely used and well-tolerated molecule in children, could provide neuroprotection in various energy deficiency disorders.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog Neurobiol 60:409–470

    Article  PubMed  CAS  Google Scholar 

  2. Andre V, Ferrandon A, Marescaux C, Nehlig A (2001) Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 47:99–117

    Article  PubMed  CAS  Google Scholar 

  3. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y (2001a) Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231–238

    Article  PubMed  CAS  Google Scholar 

  4. Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, Imai Y (2001b) Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 918:176–181

    Article  PubMed  CAS  Google Scholar 

  5. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298–304

    Article  PubMed  CAS  Google Scholar 

  6. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646–653

    Article  PubMed  CAS  Google Scholar 

  7. Cavanagh JB, Harding BN (1994) Pathogenic factors underlying the lesions in Leigh’s disease. Tissue responses to cellular energy deprivation and their clinico-pathological consequences. Brain 117(Pt 6):1357–1376

    Article  PubMed  Google Scholar 

  8. Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JC, Guilloteau D (1999) Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291:648–654

    PubMed  CAS  Google Scholar 

  9. Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M, Siliquini S, Autuori A, Picconi B, Spillantini MG, Fedele E, Pittaluga A, Raiteri M, Calabresi P (2008) Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28:8040–8052

    Article  PubMed  CAS  Google Scholar 

  10. D’Astous M, Morissette M, Di Paolo T (2004) Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 47:1180–1188

    Article  PubMed  CAS  Google Scholar 

  11. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K (1998) Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 358:351–359

    Article  PubMed  CAS  Google Scholar 

  12. Gibbs JE, Walker MC, Cock HR (2006) Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 47:469–478

    Article  PubMed  CAS  Google Scholar 

  13. Groenendaal F, Benders MJ, de Vries LS (2006) Pre-wallerian degeneration in the neonatal brain following perinatal cerebral hypoxia-ischemia demonstrated with MRI. Semin Perinatol 30:146–150

    Article  PubMed  Google Scholar 

  14. Iqbal S, Baziany A, Gordon S, Wright S, Hussain M, Miyashita H, Shuaib A, Hasan Rajput A (2002) Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res 946:162–170

    Article  PubMed  CAS  Google Scholar 

  15. Jones-Humble SA, Morgan PF, Cooper BR (1994) The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson’s disease. Life Sci 54:245–252

    Article  PubMed  CAS  Google Scholar 

  16. Kapoor R (2008) Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 274:54–56

    Article  PubMed  CAS  Google Scholar 

  17. Kilbourn MR, Kuszpit K, Sherman P (2000) Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35:250–255

    Article  PubMed  CAS  Google Scholar 

  18. Lagrue E, Chalon S, Bodard S, Saliba E, Gressens P, Castelnau P (2007) Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatr Res 62:14–19

    Article  PubMed  CAS  Google Scholar 

  19. Lagrue E, Abert B, Nadal L, Tabone L, Bodard S, Medja F, Lombes A, Chalon S, Castelnau P (2009) MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood. Metab Brain Dis 24:321–335

    Article  PubMed  CAS  Google Scholar 

  20. Lee WT, Shen YZ, Chang C (2000) Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience 95:89–95

    Article  PubMed  CAS  Google Scholar 

  21. Li X, Bijur GN, Jope RS (2002) Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4:137–144

    Article  PubMed  CAS  Google Scholar 

  22. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142–149

    Article  PubMed  CAS  Google Scholar 

  23. Meldrum BS (1996) Update on the mechanism of action of antiepileptic drugs. Epilepsia 37:S4–S11

    Article  PubMed  CAS  Google Scholar 

  24. Obrenovitch TP, Urenjak J (1998) Glutamate release inhibitors: a critical assessment of their action mechanism. Amino Acids 14:143–150

    Article  PubMed  CAS  Google Scholar 

  25. Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F (2007) The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 48:1842–1849

    Article  PubMed  CAS  Google Scholar 

  26. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135–142

    PubMed  CAS  Google Scholar 

  27. Sabers A, Gram L (2000) Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 60:23–33

    Article  PubMed  CAS  Google Scholar 

  28. Saudubray J-M, Charpentier C (1995) Clinical phenotypes: diagnosis/algoritms. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. Mc Graw-Hill, New York, pp 327–400

  29. Schulz JB, Matthews RT, Henshaw DR, Beal MF (1996) Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71:1043–1048

    Article  PubMed  CAS  Google Scholar 

  30. Serteser M, Ozben T, Gumuslu S, Balkan S, Balkan E (2002) Lipid peroxidation in rat brain during focal cerebral ischemia: prevention of malondialdehyde and lipid conjugated diene production by a novel antiepileptic, lamotrigine. Neurotoxicology 23:111–119

    Article  PubMed  CAS  Google Scholar 

  31. Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT (1993) Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol Aging 14:295–301

    Article  PubMed  CAS  Google Scholar 

  32. Stefani A, Spadoni F, Bernardi G (1997) Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147:115–122

    Article  PubMed  CAS  Google Scholar 

  33. von Wegerer J, Hesslinger B, Berger M, Walden J (1997) A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 7:77–81

    Article  Google Scholar 

  34. Williams AJ, Bautista CC, Chen RW, Dave JR, Lu XC, Tortella FC, Hartings JA (2006) Evaluation of gabapentin and ethosuximide for treatment of acute nonconvulsive seizures following ischemic brain injury in rats. J Pharmacol Exp Ther 318:947–955

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank M.-C. Furon for technical assistance with animal handling, L. Garreau, M-P. Vilar, and J. Vergotte for contributive support on experiments, and C. Hoinard for expert contribution to statistical analysis. The authors also thank F. Paillard for editing the manuscript. This work was supported by fellowships from the Fondation pour la Recherche Medicale (FRM) and from the DRASS Region Centre, France, to S. Arpin.

Author information

Affiliations

Authors

Corresponding author

Correspondence to P. Castelnau.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Arpin, S., Lagrue, E., Bodard, S. et al. Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study. Metab Brain Dis 24, 453 (2009). https://doi.org/10.1007/s11011-009-9144-7

Download citation

Keywords

  • Basal ganglia
  • Mitochondria
  • MPTP
  • Leigh syndrome
  • Neuroprotection
  • Anticonvulsant